Under one in 10 people who could benefit from obesity jabs including Wegovy are able to get them, caution the WHO as it releases its inaugural advice on the medications.
Given over a billion people worldwide currently living with obesity, it is advocating for increased and just availability to these injectable treatments.
According to estimates, over two billion will be living with obesity by 2030 unless action is taken.
"The latest guidelines acknowledges that excess weight is a lifelong illness that can be addressed with thorough and ongoing care," stated WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and logistical bottlenecks are significant obstacles to widespread access to the jabs that can aid individuals in losing significant body mass, explains the body.
Weight-Loss Drug Shortage
Even in the present most favorable outlook, the manufacturing of such drugs could only cover around 100 million people – less than 10% of eligible patients, per the health organization.
The recommendation encourages countries and companies to widen availability, via measures like patent sharing.
Exclusive production rights on a key compound – the primary component of the drug Wegovy – is scheduled to end in multiple nations in 2026.
The Way Obesity Drugs Function
GLP-1 drugs imitate a biological compound to delay gastric emptying, reduce hunger and boost feelings of fullness so users eat less.
Patients typically start to lose weight after several weeks of beginning the regular doses.
Research suggests patients may put most of the weight back on within a year of halting the medication, as their usual hunger return.
Being carrying excess weight elevates your chance for developing health problems, including diabetes, cardiovascular issues, brain attack, and specific malignancies.
Obesity concerns individuals in countries worldwide and was responsible for 3.7 million deaths worldwide in 2024, according to the health agency.
